BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang MD, Sun LY, Qian GJ, Li C, Gu LH, Yao LQ, Diao YK, Pawlik TM, Lau WY, Huang DS, Shen F, Yang T. Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study. Int J Surg 2022;105:106843. [PMID: 35995351 DOI: 10.1016/j.ijsu.2022.106843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang YQ, Wen ZY, Liu XY, Ma ZH, Liu YE, Cao XY, Hou L, Xie H. Current status and prospect of treatments for recurrent hepatocellular carcinoma. World J Hepatol 2023;15:129-50. [PMID: 36926237 DOI: 10.4254/wjh.v15.i2.129] [Reference Citation Analysis]
2 Yao M, Liang S, Cheng B. Role of exosomes in hepatocellular carcinoma and the regulation of traditional Chinese medicine. Front Pharmacol 2023;14:1110922. [PMID: 36733504 DOI: 10.3389/fphar.2023.1110922] [Reference Citation Analysis]
3 Wang J, Wu R, Sun JY, Lei F, Tan H, Lu X. An overview: Management of patients with advanced hepatocellular carcinoma. Biosci Trends 2022;16:405-25. [PMID: 36476621 DOI: 10.5582/bst.2022.01109] [Reference Citation Analysis]
4 Huo TI, Ho SY, Liao JI. A commentary on "Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study" (Int J Surg 2022;105:106843). Int J Surg 2022;:106910. [PMID: 36150655 DOI: 10.1016/j.ijsu.2022.106910] [Reference Citation Analysis]